Avanafil

Avanafil is a potent and highly selective inhibitor of phosphodiesterase-5 (PDE-5), which is the predominant PDE isoenzyme in human corpora cavernosa. In there, nitric oxide (NO) activates the enzyme guanylate cyclase, which results in increased levels of cGMP. Avanafil enhances the effect of NO by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. There are reports that avanafil has a favorable PDE-5 selectivity profile compare to that of other PDE-5 inhibitors, such as sildenafil citrate [S0986]. (The product is for research purpose only.)

References

• Avanafil, a Potent and Highly Selective Phosphodiesterase-5 Inhibitor for Erectile Dysfunction
• J. Kotera, H. Mochida, H. Inoue, T. Noto, K. Fujishige, T. Sasaki, T. Kobayashi, K. Kojima, S. Yee, Y. Yamada, K. Kikkawa, K. Omori, J. Urol. 2012, 188, 668.
• PDE5 inhibitors: considerations for preference and long-term adherence (a review)
• W. B. Smith, I. R. McCaslin, A. Gokce, S. H. Mandava, L. Trost, W. J. Hellstrom, Int. J. Clin. Pract. 2013, 67, 768.
• Development and validation of RP-HPLC method for simultaneous estimation of avanafil and dapoxentine hydrochloride in bulk and dosage form
• R. Kashyap, U. Srinivasa, K. Badodaria, World J. Pharm. Pharm. Sci. 2014, 3, 1697.